Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with brugada syndrome with and without SCN5A mutation

Masato Murakami, Kazufumi Nakamura, Kengo F. Kusano, Hiroshi Morita, Koji Nakagawa, Masamichi Tanaka, Takeshi Tada, Norihisa Toh, Nobuhiro Nishii, Satoshi Nagase, Yoshiki Hata, Kunihisa Kohno, Daiji Miura, Tohru Ohe, Hiroshi Itoh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated. The purpose of this study was to assess the efficacy of low-dose bepridil (100 mg/day) for VF prevention in patients with Brugada syndrome with and without SCN5A mutation. Among 130 patients with Brugada-type electrocardiogram (ECG), low-dose bepridil was administered to seven patients because of repetitive VF episodes, including three with and four without SCN5A mutation. Preventive effect for VF recurrence and changes of the ECG and the signal-averaged ECG were evaluated. Frequencies of VF episodes were reduced after treatment with low-dose bepridil in all three patients with the SCN5A mutation (before: 0.33 versus after: 0.02 episodes/month, P <0.01), but not in all four patients without the SCN5A mutation (before: 0.43 versus after: 2.94 episodes/month, P = nonsignificant). Levels of ST-segment elevation at J points and duration of low-amplitude signals less than 40 μV in the terminal filtered QRS complex (LAS40) in signal-averaged ECG were improved exclusively in patients with the SCN5A mutation. Treatment with bepridil prevented recurrence of VF along with improvement of ST elevation and LAS40 in patients with Brugada syndrome with the SCN5A mutation.

Original languageEnglish
Pages (from-to)389-395
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume56
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Bepridil
Brugada Syndrome
Ventricular Fibrillation
Mutation
Electrocardiography
Recurrence

Keywords

  • bepridil
  • Brugada syndrome
  • late potential
  • SCN5A mutation
  • signal-averaged electrocardiogram
  • ventricular fibrillation

ASJC Scopus subject areas

  • Pharmacology
  • Cardiology and Cardiovascular Medicine

Cite this

Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with brugada syndrome with and without SCN5A mutation. / Murakami, Masato; Nakamura, Kazufumi; Kusano, Kengo F.; Morita, Hiroshi; Nakagawa, Koji; Tanaka, Masamichi; Tada, Takeshi; Toh, Norihisa; Nishii, Nobuhiro; Nagase, Satoshi; Hata, Yoshiki; Kohno, Kunihisa; Miura, Daiji; Ohe, Tohru; Itoh, Hiroshi.

In: Journal of Cardiovascular Pharmacology, Vol. 56, No. 4, 10.2010, p. 389-395.

Research output: Contribution to journalArticle

Murakami, Masato ; Nakamura, Kazufumi ; Kusano, Kengo F. ; Morita, Hiroshi ; Nakagawa, Koji ; Tanaka, Masamichi ; Tada, Takeshi ; Toh, Norihisa ; Nishii, Nobuhiro ; Nagase, Satoshi ; Hata, Yoshiki ; Kohno, Kunihisa ; Miura, Daiji ; Ohe, Tohru ; Itoh, Hiroshi. / Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with brugada syndrome with and without SCN5A mutation. In: Journal of Cardiovascular Pharmacology. 2010 ; Vol. 56, No. 4. pp. 389-395.
@article{a3443edbdf6646b09857e48a7c6a911d,
title = "Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with brugada syndrome with and without SCN5A mutation",
abstract = "It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated. The purpose of this study was to assess the efficacy of low-dose bepridil (100 mg/day) for VF prevention in patients with Brugada syndrome with and without SCN5A mutation. Among 130 patients with Brugada-type electrocardiogram (ECG), low-dose bepridil was administered to seven patients because of repetitive VF episodes, including three with and four without SCN5A mutation. Preventive effect for VF recurrence and changes of the ECG and the signal-averaged ECG were evaluated. Frequencies of VF episodes were reduced after treatment with low-dose bepridil in all three patients with the SCN5A mutation (before: 0.33 versus after: 0.02 episodes/month, P <0.01), but not in all four patients without the SCN5A mutation (before: 0.43 versus after: 2.94 episodes/month, P = nonsignificant). Levels of ST-segment elevation at J points and duration of low-amplitude signals less than 40 μV in the terminal filtered QRS complex (LAS40) in signal-averaged ECG were improved exclusively in patients with the SCN5A mutation. Treatment with bepridil prevented recurrence of VF along with improvement of ST elevation and LAS40 in patients with Brugada syndrome with the SCN5A mutation.",
keywords = "bepridil, Brugada syndrome, late potential, SCN5A mutation, signal-averaged electrocardiogram, ventricular fibrillation",
author = "Masato Murakami and Kazufumi Nakamura and Kusano, {Kengo F.} and Hiroshi Morita and Koji Nakagawa and Masamichi Tanaka and Takeshi Tada and Norihisa Toh and Nobuhiro Nishii and Satoshi Nagase and Yoshiki Hata and Kunihisa Kohno and Daiji Miura and Tohru Ohe and Hiroshi Itoh",
year = "2010",
month = "10",
doi = "10.1097/FJC.0b013e3181f03c2f",
language = "English",
volume = "56",
pages = "389--395",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with brugada syndrome with and without SCN5A mutation

AU - Murakami, Masato

AU - Nakamura, Kazufumi

AU - Kusano, Kengo F.

AU - Morita, Hiroshi

AU - Nakagawa, Koji

AU - Tanaka, Masamichi

AU - Tada, Takeshi

AU - Toh, Norihisa

AU - Nishii, Nobuhiro

AU - Nagase, Satoshi

AU - Hata, Yoshiki

AU - Kohno, Kunihisa

AU - Miura, Daiji

AU - Ohe, Tohru

AU - Itoh, Hiroshi

PY - 2010/10

Y1 - 2010/10

N2 - It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated. The purpose of this study was to assess the efficacy of low-dose bepridil (100 mg/day) for VF prevention in patients with Brugada syndrome with and without SCN5A mutation. Among 130 patients with Brugada-type electrocardiogram (ECG), low-dose bepridil was administered to seven patients because of repetitive VF episodes, including three with and four without SCN5A mutation. Preventive effect for VF recurrence and changes of the ECG and the signal-averaged ECG were evaluated. Frequencies of VF episodes were reduced after treatment with low-dose bepridil in all three patients with the SCN5A mutation (before: 0.33 versus after: 0.02 episodes/month, P <0.01), but not in all four patients without the SCN5A mutation (before: 0.43 versus after: 2.94 episodes/month, P = nonsignificant). Levels of ST-segment elevation at J points and duration of low-amplitude signals less than 40 μV in the terminal filtered QRS complex (LAS40) in signal-averaged ECG were improved exclusively in patients with the SCN5A mutation. Treatment with bepridil prevented recurrence of VF along with improvement of ST elevation and LAS40 in patients with Brugada syndrome with the SCN5A mutation.

AB - It has been reported that bepridil prevents ventricular fibrillation (VF) in patients with Brugada syndrome, but the comparative efficacy with and without mutation in the SCN5A gene has not been elucidated. The purpose of this study was to assess the efficacy of low-dose bepridil (100 mg/day) for VF prevention in patients with Brugada syndrome with and without SCN5A mutation. Among 130 patients with Brugada-type electrocardiogram (ECG), low-dose bepridil was administered to seven patients because of repetitive VF episodes, including three with and four without SCN5A mutation. Preventive effect for VF recurrence and changes of the ECG and the signal-averaged ECG were evaluated. Frequencies of VF episodes were reduced after treatment with low-dose bepridil in all three patients with the SCN5A mutation (before: 0.33 versus after: 0.02 episodes/month, P <0.01), but not in all four patients without the SCN5A mutation (before: 0.43 versus after: 2.94 episodes/month, P = nonsignificant). Levels of ST-segment elevation at J points and duration of low-amplitude signals less than 40 μV in the terminal filtered QRS complex (LAS40) in signal-averaged ECG were improved exclusively in patients with the SCN5A mutation. Treatment with bepridil prevented recurrence of VF along with improvement of ST elevation and LAS40 in patients with Brugada syndrome with the SCN5A mutation.

KW - bepridil

KW - Brugada syndrome

KW - late potential

KW - SCN5A mutation

KW - signal-averaged electrocardiogram

KW - ventricular fibrillation

UR - http://www.scopus.com/inward/record.url?scp=77958457188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958457188&partnerID=8YFLogxK

U2 - 10.1097/FJC.0b013e3181f03c2f

DO - 10.1097/FJC.0b013e3181f03c2f

M3 - Article

C2 - 20625312

AN - SCOPUS:77958457188

VL - 56

SP - 389

EP - 395

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 4

ER -